You track competitor approvals, designations and label changes against your own portfolio. ClinicaLister puts approval status, labels and designations right next to the trial — so the three-system merge that used to eat your morning is already done. Exclusivity and Orange Book planning is the one thing it cannot carry; the limitations say why.
The highest-leverage things ClinicaLister does for a regulatory affairs specialist.
Every recurring activity, mapped to what ClinicaLister does — on which surface (the App, the MCP graph, or both), the time it saves, and how confident that claim is.
| Activity | What ClinicaLister does | Surface | Time saved | Confidence |
|---|---|---|---|---|
| Regulatory status tracker per trial | Approval status is linked to each trial automatically, in one filterable drug profile. | Both | eliminates the hand-join; hours → minutes | High |
| Designation tracking (Orphan / FT / BT) | Orphan, fast-track, breakthrough, and REMS status per drug, aggregated into a portfolio-wide designation map. | Both | auto map vs a maintained spreadsheet | High |
| REMS + DEA schedule monitoring | REMS and DEA schedule are dedicated, filterable fields on every drug. | App | instant filter vs REMS@FDA lookups | High |
| Exclusivity end-date on a named drug | Returned where the FDA record carries it — 1.8% of drug records. An exclusivity WATCH across a portfolio is not possible on that coverage and is not offered. | Both | per-drug lookup only | Low |
| Patent fields on a named drug | Patent data is present on 4.4% of FDA drug records and Purple Book patents on 0.05%. There is no Orange Book ingest, no first-generic date, and no cliff timeline. | Both | per-drug lookup only | Low |
| Label surveillance (boxed warnings, CI) | A label-intelligence report pulls boxed warnings and contraindications straight from the official FDA label. | MCP | fast scan — retrieval, not alerting | Medium |
| Competitor approvals & designations | The same regulatory fields on every competitor drug, summarised in a regulatory-advantage scorecard. | Both | visible without separate research | Medium |
| US vs EU divergence reconciliation | EMA status and EU trial links per trial, plus a side-by-side FDA-vs-EMA comparison. | Both | one view, not two portals | High |
| Protocol amendment / change tracking | Endpoint, status, and eligibility changes are detected field by field, with a full audit trail of what changed and when. | Both | endpoint / status changes in hours | Medium |
| Device regulatory profile | A consolidated device profile with class, regulation, and establishment registrations. | Both | one device identity, not many lookups | High |
| Portfolio regulatory summary / board report | One-click Excel export plus source-cited reports — a board pack in minutes. | Both | reports in minutes, fully sourced | High |
| Registry compliance (posting deadlines) | Registry posting is reflected and changes are flagged — visibility, not a deadline workflow. | App | visibility only | Low |
| Author / submit dossiers (IND/NDA/BLA/MAA) | Not supported — ClinicaLister is not a submission system of record. | — | — | n/a |
| HA correspondence, commitments, minutes | Not supported — public data only, no internal correspondence. | — | — | n/a |
| Regulatory strategy advice / label negotiation | Decision support only — it surfaces the evidence; the strategy is yours. | — | — | n/a |
Straight answers on where ClinicaLister stops today — so there are no surprises.
Patent and exclusivity coverage is thin, and this is the honest number: of 29,777 FDA drug records we hold patents on 4.4%, exclusivity end-dates on 1.8%, and Purple Book patents on 0.05% (measured 2026-08-17). That supports a per-drug lookup where the data happens to exist — it does NOT support a portfolio patent-cliff or loss-of-exclusivity timeline, and we would rather say so than return an empty chart that reads as "nothing expiring". A full Orange Book / Purple Book feed is not yet ingested.
Exclusivity shows as end-dates, not a duration chart — there's no Gantt of overlapping exclusivities in the app yet (an on-demand report partially fills the gap).
No formal "amendment" object — changes are detected field by field, not labelled or versioned as regulatory protocol amendments.
Public FDA / EMA data only — no internal correspondence, non-public filings, or commitment tracking.
Not a system of record for submissions — it doesn't author, route, or submit dossiers, or manage posting-deadline obligations. Compliance visibility, not workflow.
Label surveillance is retrieval, not validated change-alerting — and none of it is regulatory advice.
Approval status, current label, REMS and orphan designation sit right next to the trial — aggregated across your whole portfolio and every competitor, with every field-level change flagged and graded.